SELLAS Life Sciences Group, Inc.

SLS
$13.50 (- $0.44 - 3.16%)
Last updated: 2026-07-08 10:47 UTC
SLS Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS81642T1007
CUSIP81642T100
Market Price13.5
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.28
Market Cap$418.7M
Book Value0.36
Price to Book7.781
Beta2.52
52w High3.0
52w Low0.85
Next Earnings DateN/A

SELLAS Life Sciences Group, Inc. trades under ticker SLS on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US81642T1007, CUSIP 81642T100. Also searched as SELLAS Life Sciences Group.

Related researchSLS stock priceSLS share price81642T100SELLAS Life Sciences Group stockSELLAS Life Sciences Group share price
About the Company
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Price History